Guest post by Dr. Nate Pennell, a board certified medical oncologist at the Taussig Cancer Center at the Cleveland Clinic. He specializes in the treatment of thoracic malignancies with a focus on lung cancer. Dr. Pennell's research interests include clinical trials using novel therapies, with a goal of facilitating the movement of new treatments from the laboratory to the clinic. Follow him on Twitter at @n8pennell.

Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?

[powerpress]

In Part 2 of 2 videos about squamous lung cancer, Dr.

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.

[powerpress]

Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014

[powerpress]

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

[powerpress]

Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.

[powerpress]